Spark Therapeutics’ (ONCE) Hold Rating Reiterated at Mizuho

Mizuho reaffirmed their hold rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a research note issued to investors on Monday, AnalystRatings.com reports. The firm currently has a $114.50 price target on the biotechnology company’s stock.

Separately, Zacks Investment Research upgraded shares of Spark Therapeutics from a sell rating to a hold rating in a report on Wednesday, July 3rd. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $87.92.

ONCE opened at $100.11 on Monday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.56 and a quick ratio of 5.59. Spark Therapeutics has a fifty-two week low of $34.53 and a fifty-two week high of $114.20. The firm has a market capitalization of $3.81 billion, a PE ratio of -47.45 and a beta of 2.07. The company’s 50-day moving average is $99.72 and its 200 day moving average is $99.50.



Several institutional investors and hedge funds have recently bought and sold shares of ONCE. Sterling Investment Advisors Ltd. acquired a new stake in shares of Spark Therapeutics in the 1st quarter worth about $68,000. CSat Investment Advisory L.P. purchased a new stake in Spark Therapeutics in the 2nd quarter valued at about $113,000. Meeder Asset Management Inc. purchased a new stake in Spark Therapeutics in the 1st quarter valued at about $121,000. Janney Montgomery Scott LLC purchased a new stake in Spark Therapeutics in the 2nd quarter valued at about $202,000. Finally, Ancora Advisors LLC purchased a new stake in Spark Therapeutics in the 2nd quarter valued at about $205,000. Institutional investors own 84.08% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

See Also: What are catch-up contributions?

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.